Toward antisense oligonucleotide therapy for cancer: ISIS compounds in clinical development

Author(s): Holmlund JT, Monia BP, Kwoh TJ, Dorr FA

Abstract

Antisense oligonucleotides offer the promise of therapeutic effect with few toxic effects, by virtue of their high selectivity. Preclinical studies have provided evidence of antisense effects in vitro and in vivo, and phase I clinical trials have demonstrated safety, feasibility and activity of antisense oligonucleotides for the treatment of cancer. This review summarizes the status of development of three anticancer antisense oligonucleotides from ISIS Pharmaceuticals.

Similar Articles

Role of Interferons in the Development of Diagnostics, Vaccines, and Therapy for Tuberculosis

Author(s): Chin KL, Anis FZ, Sarmiento ME, Norazmi MN, Acosta A, et al.

Role of Type I and II Interferons in Colorectal Cancer and Melanoma

Author(s): Di Franco S, Turdo A, Todaro M, Stassi G

Innate immune response induced by gene delivery vectors

Author(s): Sakurai H, Kawabata K, Sakurai F, Nakagawa S, Mizuguchi H, et al.

Analysis of Pro-inflammatory Cytokine and Type II Interferon Induction by Nanoparticles

Author(s): Potter TM, Neun BW, Rodriguez JC, Ilinskaya AN, Dobrovolskaia MA, et al.

More than 70 years of pyrogen detection: Current state and future perspectives

Author(s): Fennrich S, Hennig U, Toliashvili L, Schlensak C, Wendel HP, et al.

Evidence for the detection of non-endotoxin pyrogens by the whole blood monocyte activation test

Author(s): Hasiwa N, Daneshian M, Bruegger P, Fennrich S, Hochadel A, et al.

International validation of novel pyrogen tests based on human monocytoid cells

Author(s): Hoffmann S, Peterbauer A, Schindler S, Fennrich S, Poole S, et al.

Nucleic acids as therapeutic agents

Author(s): Alvarez-Salas LM

Immune stimulation--a class effect of phosphorothioate oligodeoxynucleotides in rodents

Author(s): Monteith DK, Henry SP, Howard RB, Flournoy S, Levin AA, et al.

Aptamers as therapeutics

Author(s): Keefe AD, Pai S, Ellington A

5'-triphosphate RNA requires base-paired structures to activate antiviral signaling via RIG-I

Author(s): Schmidt A, Schwerd T, Hamm W, Hellmuth JC, Cui S, et al.